许多最新的研究表明，衰老以及同衰老相关的疾病与不可控的炎症反应有关。韩国釜山国立大学药学院Jae Heun Chung等人通过对过氧化物酶体增殖物激活受体（PPAR）研究认为，在衰老过程中，核受体亚家族转录因子的减少，过氧化物酶体增殖物激活受体的活化同炎症抑制水平的提高有很密切的关系，PPAR在体内和体外的抗炎症反应都说明了PPARs在炎症疾病发病机制中起着很重要的作用。PPAR属于由配体激活的Ⅱ型核受体超家族成员，有三种异构形式，即α、β和γ型，广泛分布于人体，主要分布于肝脏、肾脏、褐色脂肪组织。
Devchand等发现了白三烯B4是PPARα的配体，PPARα的激活可导致白三烯B4分解，限制炎症反应因此，PPAR的激活对动脉粥样硬化的并发症如心肌梗死和斑块破裂具有保护作用。
不仅如此，PPARs的活化还可以改善包括糖尿病、高血压和肥胖等在内的胰岛素抵抗综合征，而且还直接作用于血管壁，从而减缓动脉粥样硬化的进程。深入的研究PPAR受体陪体的分子机制，将为我们开启治疗动脉粥样硬化、血管性疾病、阿尔茨海默症和癌症等顽疾的大门。相关文章发表在爱思唯尔期刊《衰老研究评论》（Ageing Research Reviews）上。（生物谷Bioon.com）
生物谷推荐原始出处：
Ageing Research Reviews，Volume 7, Issue 2, April 2008, Pages 126-136，Jae Heun Chung，Hae Young Chung
Molecular mechanism of PPAR in the regulation of age-related inflammation
Jae Heun Chunga, Arnold Y. Seob, Sang Woon Chunga, Mi Kyung Kimc, Christiaan Leeuwenburghb, Byung Pal Yud and Hae Young Chunga, b, ,
aDepartment of Pharmacy, College of Pharmacy, Pusan National University, San 30, Jang-jun-dong, Geomjung-ku, Busan 609-735, South Korea
bDepartment of Aging and Geriatrics, College of Medicine, Institute on Aging, Biochemistry of Aging Laboratory, University of Florida, Gainesville, FL 36210-0107, USA
cLongevity Life Science & Technology Institutes, Pusan National University, San 30, Jang-jun-dong, Geomjung-ku, Busan 609-735, South Korea
dDepartment of Physiology, The University of Texas Health Science Center at San Antonio, TX 78229-3900, USA
Evidence from many recent studies has linked uncontrolled inflammatory processes to aging and aging-related diseases. Decreased a nuclear receptor subfamily of transcription factors, peroxisome proliferator-activated receptors (PPARs) activity is closely associated with increased levels of inflammatory mediators during the aging process. The anti-inflammatory action of PPARs is substantiated by both in vitro and in vivo studies that signify the importance of PPARs as major players in the pathogenesis of many inflammatory diseases. In this review, we highlight the molecular mechanisms and roles of PPARα, γ in regulation of age-related inflammation. By understanding these current findings of PPARs, we open up the possibility of developing new therapeutic agents that modulate these nuclear receptors to control various inflammatory diseases such as atherosclerosis, vascular diseases, Alzheimer's disease, and cancer.
